Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.48 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | NRP1 | O14786 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.42 |
| ▸ | CALCR | P30988 | 2/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194515 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL21043608 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL7263725 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12899263 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL1247795 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12261069 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL13084631 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL14227389 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12899266 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12237919 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119331057-A | T8 synthetic product and application thereof | 海南盛世传恩医疗科技有限公司 | 2025-01-21 | — | — | CN | claimed |
| US-20240156960-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | DNARx (US) | 2024-05-16 | — | — | US | claimed |
| CN-115089734-B | Carbonized MOFs nanoparticle carrying phagocytic peptide, preparation method and application in imaging and treating retinoblastoma | 重庆医科大学附属第二医院 | 2023-11-03 | — | — | CN | claimed |
| CN-116615233-A | Systems and methods for expressing biomolecules in a subject | DNARX公司 | 2023-08-18 | — | — | CN | claimed |
| EP-4216935-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | Dnarx (US) | 2023-08-02 | — | — | EP | claimed |
| US-20230212610-A1 | NUCLEIC ACID EXPRESSION USING SUBCUTANEOUS ADMINISTRATION | DNARx (US) | 2023-07-06 | — | — | US | claimed |
| US-20230172869-A1 | A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-08 | — | — | US | claimed |
| EP-4138856-A1 | A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-01 | — | — | EP | claimed |
| CN-115089734-A | Carbonized MOFs nanoparticles carrying deglutition promoting peptides, preparation method and application in imaging and treating retinoblastoma | 重庆医科大学附属第二医院 | 2022-09-23 | — | — | CN | claimed |
| WO-2022067091-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | DNARx (US) | 2022-03-31 | — | — | WO | claimed |
| WO-2026089754-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026089752-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | Finitus, LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | FINITUS LLC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | KOSAK KENNETH MICHAEL (US) | 2026-04-21 | — | — | US | disclosed |
| US-4786737-A | PREPARATION OF TUFTSIN AND LISINOPRIL | AJINOMOTO CO., INC. (JP) | 1988-11-22 | — | — | US | disclosed |
| US-4720554-A | Aromatic sulfonic acid salts of a proline derivative | AJINOMOTO CO., INC. (JP) | 1988-01-19 | — | — | US | disclosed |
| WO-1987004440-A1 | HEPTANOYL-GLU-ASP-ALA-AMINO ACID IMMUNOSTIMULANTS | PFIZER INC. (US) | 1987-07-30 | — | — | WO | disclosed |
| EP-0178845-A2 | Peptide-substituted heterocyclic immunostimulants | PFIZER INC. (US) | 1986-04-23 | — | — | EP | disclosed |
| EP-0157572-A2 | Acyltripeptide immunostimulants | PFIZER INC. (US) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | PABPC1, PABPC4, ABCG2 | OPRM1 1611/4885OPRK1 3265/4885GRB2 3257/4885 |
| US-20240156960-A1 | SYSTEMS AND METHODS FOR EXPRESSING BIOMOLECULES IN A SUBJECT | ACE2, ACE, IGF2BP2 | OPRM1 1353/4885OPRK1 1752/4885GRB2 867/4885 |
| US-20260108583-A1 | COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES | MUC1, VIP, LGALS4 | OPRM1 2580/4885OPRK1 2000/4885GRB2 4117/4885 |
| US-20230212610-A1 | NUCLEIC ACID EXPRESSION USING SUBCUTANEOUS ADMINISTRATION | FABP4, APMAP, IGF2BP2 | OPRM1 1698/4885OPRK1 3997/4885GRB2 1826/4885 |
| US-20260108467-A1 | COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES | FGF23, FIBP, PTMS | OPRM1 2774/4885OPRK1 3675/4885GRB2 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.